急性髓细胞白血病7.pdfVIP

Ann Hematol (2005) 84: 557–564 DOI 10.1007/s00277-005-1046-0 ORIGINAL ARTICLE A. Wrzesień-Kuś . T. Robak . A. Wierzbowska . E. Lech-Marańda . A. Pluta . E.Wawrzyniak . A. Krawczyńska . K. Kuliczkowski . G. Mazur . M. Kiebiński . A. Dmoszyńska . M. Wach . A. Hellmann . W. Baran . J. Hołowiecki . S. Kyrcz-Krzemień . S. Grosicki A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group Received: 8 January 2005 / Accepted: 2 April 2005 / Published online: 27 April 2005 # Springer-Verlag 2005 Abstract Purine nucleoside analogues, cladribine (2-chlo- toxicity of induction treatment consisting of 2-CdA (5 mg/ 2 2 2 rodeoxyadenosine, 2-CdA) and fludarabine (FAMP) are m ), Ara-C (2 g/m ), mitoxantrone (MIT, 10 mg/m ) and active agents in acute myeloid leukemias (AMLs). Syner- granulocyte colony-stimulating factor (G-CSF) (CLAG-M) gistic interaction between FAMP or 2-CdA with cytarabine in refractory AML. In case of partial remission, a second (cytosine arabinoside, Ara-C) has been demonstrated in CLAG-M was administered. Patients in complete remission preclinical and clinical studies. The current multicenter (CR) received consolidation courses based on high-dose phase II study was initiated to evaluate the efficacy and Ara-C and MIT with or without 2-CdA. Forty-three patients from five centers were registered: 25 primary resistant and 18 relapsed. CR was achieved in 21 (49%) pa